Advertisement

Topics

NightstaRx initiates Phase I/II trial of AAV-XLRPGR therapy to treat XLRP

20:00 EDT 19 Mar 2017 | Net Resources International

UK-based biopharmaceutical company NightstaRx (Nightstar) has initiated enrolment and dosing in a Phase I/II clinical trial of its gene therapy 'AAV- XLRPGR' for the treatment of patients with X-linked retinitis pigmentosa (XLRP).

Original Article: NightstaRx initiates Phase I/II trial of AAV-XLRPGR therapy to treat XLRP

NEXT ARTICLE

More From BioPortfolio on "NightstaRx initiates Phase I/II trial of AAV-XLRPGR therapy to treat XLRP"

Quick Search
Advertisement
 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...